GILD · News · 20261030N
Canadian Reimbursement Access
GILEAD SCIENCES, INC. · 2026-10-30 · Importance 37 · Surprise 42 · In source text
Gilead secured a pan-Canadian public reimbursement agreement for Livdelzi (seladelpar), which treats primary biliary cholangitis. The agreement with the pan Canadian Pharmaceutical Alliance supports future public formulary listings and could broaden access across Canadian provinces. The report did not provide a financial value for the agreement.
Key facts
- Gilead secured a pan-Canadian public reimbursement agreement for LYVDELZI (seladelpar) for primary biliary cholangitis. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Gilead secured a pan-Canadian public reimbursement agreement for LYVDELZI (seladelpar) for primary biliary cholangitis. |